Bone Biologics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Bone Biologics is forecast to grow earnings at 4.9% per annum. EPS is expected to grow by 53.7% per annum.

Anahtar bilgiler

4.9%

Kazanç büyüme oranı

53.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.1%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:BBLG - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-5	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
6/30/2024	N/A	-5	-7	-7	N/A
3/31/2024	N/A	-6	-10	-10	N/A
12/31/2023	N/A	-9	-10	-10	N/A
9/30/2023	N/A	-7	-9	-9	N/A
6/30/2023	N/A	-6	-7	-7	N/A
3/31/2023	N/A	-5	-4	-4	N/A
12/31/2022	N/A	-1	-4	-4	N/A
9/30/2022	N/A	-3	-2	-2	N/A
6/30/2022	N/A	-2	-2	-2	N/A
3/31/2022	N/A	-2	-2	-2	N/A
12/31/2021	N/A	-2	-1	-1	N/A
9/30/2021	N/A	-2	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-2	0	0	N/A
12/31/2020	N/A	-2	0	0	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	-1	-1	N/A
3/31/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-4	-4	-4	N/A
6/30/2019	N/A	-4	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-6	-4	-4	N/A
6/30/2018	N/A	-8	-3	-3	N/A
3/31/2018	N/A	-6	N/A	-3	N/A
12/31/2017	N/A	-7	N/A	-3	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-16	N/A	-5	N/A
3/31/2017	N/A	-22	N/A	-6	N/A
12/31/2016	N/A	-26	N/A	-7	N/A
9/30/2016	N/A	-24	N/A	-7	N/A
6/30/2016	N/A	-23	N/A	-7	N/A
3/31/2016	N/A	-19	N/A	-6	N/A
12/31/2015	N/A	-14	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-4	N/A
6/30/2015	N/A	-6	N/A	-4	N/A
3/31/2015	N/A	-6	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	0	N/A
3/31/2014	N/A	-1	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BBLG is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: BBLG is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: BBLG is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if BBLG's revenue is forecast to grow faster than the US market.

Yüksek Büyüme Geliri: BBLG is forecast to have no revenue next year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if BBLG's Return on Equity is forecast to be high in 3 years time

Bone Biologics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased to US$4.88

Price target decreased to US$4.88

Recent updates

Bone Biologics Corporation Appoints Phillip Meikle to Board of Directors

Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective Immediately

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.

Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024

New major risk - Share price stability

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.

Bone Biologics Corporation has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Bone Biologics Corporation has filed a Follow-on Equity Offering.

Bone Biologics Corporation Announces Board Changes

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation Receives Non-Compliance Notice From Nasdaq

New major risk - Financial position

Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023

New major risk - Share price stability

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price Requirement

Bone Biologics Corporation Resigns Stephen Laneve as Director

Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price Requirement

Price target decreased to US$4.88

Price target decreased to US$4.88

Bone Biologics Corporation has completed a Composite Units Offering.

Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.

Bone Biologics prices $5.1M underwritten public offering

Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Less than half of directors are independent

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin